This study was designed to assess the costeffectiveness of erlotinib compared with docetaxel in the second-line management of advanced non-small-cell lung cancer (NSCLC) within the UK National Health Service (NHS). A health-state transition model, based on two randomized phase III studies of erlotinib or docetaxel versus best supportive care, was used to estimate total direct costs, quality-adjusted life years (QALYs) and the subsequent net monetary benefit. Erlotinib was associated with a reduction in total costs (£13 730 versus £13 956) and improved outcomes (total QALYs of 0.238 versus 0.206) compared with docetaxel. Sensitivity analyses demonstrated the robustness of this analysis. In summary, erlotinib appeared to generate similar overall survival, an increase in QALYs and a small reduction in total NHS costs compared with docetaxel, due to lower adverse event and drug administration costs. Consequently, from a health economics perspective for the treatment of relapsed stage III -IV NSCLC patients in the UK, erlotinib has advantages over docetaxel.
Introduction
In the UK, lung cancer accounts for 14% of new malignancies and is the most common cause of cancer deaths. 1, 2 The majority (80 -85%) of cases are non-small-cell lung cancer (NSCLC), which generally presents at an advanced stage (stage III -IV), when surgical resection is rarely possible. The objectives of treatment for advanced NSCLC are to extend survival and to improve or maintain quality of life (QoL). The QoL considerations are particularly important since advanced NSCLC is commonly associated with debilitating symptoms, such as cough, dyspnoea and pain. 3 -5 Standard first-line treatment is platinum- G Lewis, M Peake, R Aultman et al. Cost-effectiveness of erlotinib versus docetaxel in NSCLC based doublet chemotherapy, which produces a response rate of 30 -40% and a time to progression of approximately 3 -4 months. 6 Second-line chemotherapy options currently include docetaxel and pemetrexed, although these agents are associated with haematological toxicity, require administration by intravenous infusion and provide limited QoL benefits. For example, in a phase III study, the recommended docetaxel dose of 75 mg/m 2 produced grade 3 -4 neutropenia in 67% of patients 7 and did not significantly improve QoL. 8 Moreover, febrile neutropenia has been reported in 6 -12% of patients treated with 75 mg/m 2 docetaxel. 9 -11 The haematological toxicities of drugs such as docetaxel and pemetrexed may predispose patients to other problems, such as infection, which may necessitate hospitalization (required for 13.4% of patients receiving docetaxel in a phase III study in 571 patients 10 ) and increase treatment costs. 12 These toxicities, the limited QoL benefits, and the inconvenience and resource consumption associated with intravenous chemotherapy, highlight the need for alternative second-line options for advanced NSCLC.
Erlotinib (Tarceva ® , OSI Pharmaceuticals Inc., Melville, NY, USA) is an orally available inhibitor of the tyrosine kinase activity of human epidermal growth factor receptor (EGFR), 13 a protein that is implicated in lung cancer tumorigenesis. 14 -16 In a large, randomized, placebo-controlled phase III study (BR.21), 17 erlotinib produced a significant survival benefit (hazard ratio 0.70, P < 0.001) in patients with advanced NSCLC who had failed at least one prior chemotherapy regimen. The magnitude of the survival benefit produced by erlotinib appears to be very similar to that observed with second-line chemotherapy options. 18 This is supported by a report showing that another EGFR tyrosine kinase inhibitor (gefitinib) produced identical overall survival to docetaxel in a head-to-head phase III study including patients with previously treated advanced NSCLC. 19 Erlotinib also confers significant symptom and QoL benefits. 17, 20 In the BR.21 study, times to deterioration of cough, dyspnoea and pain were significantly longer in erlotinib-treated patients compared with those receiving placebo, and significant differences favouring erlotinib were noted for physical function and global QoL. 20 The most common adverse events associated with erlotinib therapy are rash and diarrhoea, which are generally mild or moderate (grade 1 or 2) and usually easy to manage. 17, 21 The present study was a cost-utility analysis to determine the incremental cost per quality-adjusted life-year (QALY) for erlotinib compared with docetaxel as secondline treatment for advanced NSCLC from the perspective of the UK National Health Service (NHS). In the UK, docetaxel has been demonstrated to be cost-effective versus best supportive care. 22 Consequently, docetaxel was considered to be the most relevant comparator for the purposes of the present analysis. Both docetaxel and erlotinib are recommended by the UK National Institute for Health and Clinical Excellence (NICE) for the second-line treatment of advanced NSCLC. 23, 24 There are currently no randomized head-to-head studies comparing erlotinib and docetaxel. Published data utilizing the NICE recommended methodology of mixed treatment comparison have, however, suggested that erlotinib has similar efficacy to docetaxel and is better tolerated. 25, 26 The lower frequency of severe treatment-related adverse events with erlotinib is likely to have
Patients and methods

PATIENT POPULATION
The patient populations used for this analysis were assumed to be equivalent to the intention-to-treat populations of two controlled, phase III studies of erlotinib and docetaxel in patients with previously treated stage IIIB -IV NSCLC. The BR.21 study 17 of 150 mg/day erlotinib versus placebo recruited 731 patients with performance status 0 -3 who had received one or two prior chemotherapy regimens. The TAX317 study 7 of 75 or 100 mg/m 2 docetaxel every 3 weeks versus best supportive care recruited 155 patients with performance status 0 -2 who had received one or more prior chemotherapy regimens; only patients receiving the approved dose of docetaxel (75 mg/m 2 ; n = 55) were included in the current analysis. 8 The baseline characteristics of patients in these trials were similar, although the greater proportion of performance status 0 -1 patients in the TAX317 study of docetaxel than in the BR.21 study of erlotinib (75% versus 66%, respectively) suggests that any bias arising from an indirect comparison of outcomes across the two trials should favour docetaxel ( Table 1 ).
OVERVIEW OF THE COST-UTILITY MODEL
A health-state transition model was used, based on three health states (progressionfree, progression and death) over a 2-year time horizon, with a 1-month cycle period and a half-cycle correction. Discounting was applied at a rate of 3.5% for year 2 of the analysis.
CLINICAL ASSUMPTIONS
The mean overall survival for erlotinib in study BR.21 was 9.56 months according to the last observed time, and 9.03 months according to the last event time (Roche data on file). Holmes et al. 22 reported a mean overall survival of 8.89 months for docetaxel in the TAX317 study, whilst in a second 27 the mean overall survival for docetaxel was 8.74 months. In the absence of a randomized head-to-head study, and considering the uncertainty associated with indirect comparisons of survival, it was assumed that mean overall survival was the same for both erlotinib and docetaxel (9.03 months). A recent publication by Hawkins et al. 25 suggests that an assumption of equivalent overall survival for erlotinib and docetaxel would be more likely to favour docetaxel.
Overall survival and progression-free survival (PFS) data from the TAX317 and BR.21 studies were used to estimate the time spent in each health state by patients receiving docetaxel or erlotinib. Tabulated Kaplan-Meier overall survival and PFS data were not available for docetaxel in the TAX317 study. As these data were essential for constructing model cycles and incorporating discounting, it was necessary to estimate distributions for overall survival and PFS for docetaxel.
Kaplan-Meier data for docetaxel were derived based on the same overall survival distribution as for erlotinib. No extrapolation of survival curves was necessary because all patients in the TAX317 study had died after 2 years. In contrast, in the BR.21 study, approximately 13% of the at-risk erlotinib-treated patients were still alive after 2 years. 17 As the mean PFS was not reported for docetaxel in TAX317 and since the BR. 21 and TAX317 studies specified treatment until disease progression, mean treatment duration was considered a necessary surrogate for mean docetaxel PFS. This parameter was, therefore, also used for erlotinib in order to ensure consistency of assumptions. Mean treatment durations were 4.11 months (125 days) for erlotinib 17 and 3.33 months (101 days) for docetaxel. 22 The assumption of equivalent PFS was evaluated within the sensitivity analysis. As for overall survival, tabulated mean PFS data were not available for docetaxel and Kaplan-Meier data for this drug were derived based on the PFS distribution observed with erlotinib. The mean time in post-progression survival was calculated as the overall survival minus the mean time in PFS (4.92 months for erlotinib and 5.56 months for docetaxel).
UTILITIES
A utility study was performed using the EuroQol EQ-5D instrument, a standardized and validated generic instrument that quantifies changes in health-related QoL (utilities) on the basis of public preferences 28 to determine utility scores for progressionfree and progression health states for both intravenous and oral therapy, as well as for significant adverse events. 29 Ideally, healthrelated QoL should be reported directly from patients and the value of the changes in health-related QoL (utilities) should be based on general population preferences. 26 It was not possible, however, in this study to adhere to this gold standard methodology when obtaining utility scores due to issues relating to local ethics approval. Nevertheless, the method used is considered a valid alternative. 30 The EQ-5D data were gathered from 154 members (considered an appropriate number at the time this utility study was carried out) of the general population from four UK sites using a visual analogue scale (VAS) and the utility scores that were determined are shown in Table 2 . Although use of a VAS is not common, it is a valuation method that was frequently used when this utility study was conducted due to its simplicity and user friendliness. Parkin and Devlin 31 addressed the common criticisms on G Lewis, M Peake, R Aultman et al.
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the use of VAS and highlighted its advantages. For the determination of QALYs, the total time spent in each health state was weighted by the relevant utility score.
The QoL data were adjusted for grade 3 -4 adverse events associated with each treatment. Where adverse events for docetaxel were reported in the BR.21 study but not in the TAX317 study (fatigue, rash), the adverse event data from the JMEI study 10 were used (Table 3 ). Adverse event rates were not adjusted for differences in trial populations since there were insufficient data from the docetaxel trial to perform such Notably, there was a much higher rate (12.7%) of febrile neutropenia with docetaxel in the JMEI study 10 than in the TAX317 study (1.8%). 7 Utility scores were obtained for all adverse events except fatigue, anorexia and infection. In these cases, a utility score equal to the progression-free health state for the treatment in question was applied. All utility decrements relating to adverse events were assumed to apply for 1 month or one cycle, with the exception of rash and fatigue (which were assumed to last for the duration of treatment, or four model cycles). This was considered reasonable because the adverse events reported appeared, in general, to last for 5 -7 days per cycle. The model did not account for any QoL benefits that may have accrued from symptomatic relief so the full benefit delivered by erlotinib in this respect may not have been captured.
HEALTHCARE RESOURCE UTILIZATION
Medical resource utilization and consequent monthly costs for the progression-free and progression health states, treatment-related adverse events and drug administration were discussed and agreed on by a panel of five UK lung cancer physicians (Table 4) . 32, 33 A consensus was reached for each health state or adverse event, although variations in the consequent costs were evaluated in the sensitivity analysis. Unit costs were derived from UK NHS reference cost sources and from figures provided by the Personal Social Services Research Unit. The 2009 health-state costs were applied for the mean duration of time spent in each health state by each patient. 
Cost input Value
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DRUG COSTS
List prices of drug costs provided by the NHS were used for this analysis. A mean body surface area of 1.77 m 2 was used to calculate the dose of docetaxel; at a dosing schedule of 75 mg/m 2 this equates to a mean dose per cycle of 133 mg. Docetaxel is supplied as vials containing 20 or 80 mg, priced at £162.75 and £534.75, respectively; this equates to a mean cost of £1023 per administration (one 80 mg and three 20 mg vials). 34 The recommended dosage of erlotinib as used in study BR.21 is 150 mg/day, with an acquisition cost of £54.38 per day. 34 Total drug costs were calculated as the cost per day multiplied by the mean duration of treatment observed in the phase III studies.
SENSITIVITY ANALYSES
The main cost and effectiveness drivers were varied across plausible ranges to evaluate the robustness of the base case results. Parameters varied, including the cost of managing febrile neutropenia, the cost of docetaxel administration, the cost of the progression-free health state, the cost of progressive disease, utility scores for PFS and progression, and the febrile neutropenia rate (including that reported for docetaxel by Hanna et al. 10 ).
In the scenario analysis, which assessed more fundamental changes in major assumptions of the model and the modelled approach, alternative scenarios that were considered included equivalent overall survival and PFS, equivalent utility scores for PFS, equivalent treatment duration and the omission of adverse event utilities from the model. In addition, the uncertainty attached to the modelled results was investigated in a probabilistic analysis in which the uncertainty in key model parameters was evaluated simultaneously using Monte Carlo simulation.
Results
For the base case analysis, the lifetime per patient costs associated with erlotinib and docetaxel were estimated by the model to be £13 730 and £13 956, respectively, from the perspective of the NHS (Table 5) , giving an incremental advantage of -£226 for erlotinib. Erlotinib was associated with lower costs for the management of treatmentrelated adverse events and drug G Lewis, M Peake, R Aultman et al.
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administration, and a lower cost of disease progression. Due to a higher drug acquisition cost and longer treatment duration, total drug costs are an additional £2140 per patient for erlotinib compared with docetaxel. The total QALYs for erlotinib and docetaxel were 0.238 and 0.206, respectively, representing an incremental advantage of 0.032 QALYs for erlotinib.
The incremental cost of -£226 for an incremental advantage of 0.032 QALYs gives a final base case incremental cost per QALY for erlotinib of -£7106, showing that erlotinib achieves greater QALYs for lower total direct NHS costs. At an assumed cost-effectiveness threshold of £30 000 per QALY, the net monetary benefit (NMB) is £1181; this is calculated by assigning a monetary value to the incremental benefit achieved (0.032 × £30 000) and subtracting the incremental cost of achieving this benefit (-£226).
ONE-WAY SENSITIVITY AND SCENARIO ANALYSES
In analyses assessing the alternative scenarios of equivalent overall survival and PFS (assumed to be 9.30 and 4.11 months, respectively, based on study BR.21), equivalent utility scores for PFS (assumed to be 0.45), equivalent treatment duration (assumed to be 125 days) and the omission of adverse event utilities from the model, erlotinib remained the dominant treatment.
The sensitivity of the cost-effectiveness estimate was further evaluated by considering the impact on the NMB of varying the main cost and effectiveness drivers across plausible ranges ( Table 6 ). The lowest NMB values were seen when the cost of docetaxel administration was reduced by 50%, the cost G Lewis, M Peake, R Aultman et al.
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of the progression health state was reduced by 50%, and the utility score for PFS for docetaxel was increased by 20%. The highest NMB values were observed when the cost of docetaxel administration was increased by 50%, the cost of the progression health state was increased by 50%, and the utility score for PFS for docetaxel was decreased by 20%.
PROBABILISTIC SENSITIVITY ANALYSES
The cost-effectiveness acceptability curve (Fig. 1) shows that at a willingness-to-pay threshold of £30 000 per QALY, erlotinib is cost-effective in approximately 70% of scenarios. Erlotinib remains cost-saving in 36% of all model iterations. Probabilistic sensitivity analysis (Fig. 2) showed that, although incremental costs per QALY gained are distributed across all four quadrants of the cost-utility plane, in the majority of scenarios erlotinib 'dominates' docetaxel and is below the acceptability threshold. The incremental costs per QALY are closely grouped around the origin, which suggests a small distribution of costs and small range of QALY values. The incremental QALY values for erlotinib ranged from -0.21 to +0.23, with incremental costs ranging from -£5765 to +£5032. Given the relatively small differences in observed cost and effects for the two interventions, the reported level of sensitivity and subsequent uncertainty around the incremental cost-effectiveness ratio is expected.
Discussion
On the basis of a £30 000 cost-effectiveness threshold (NICE suggests £20 000 -£30 000 per QALY gained 35 ) the base case and sensitivity analyses presented here suggest that erlotinib is cost-effective when compared with docetaxel as a second-line treatment for advanced NSCLC in the UK. In the base case analysis, the incremental total cost per QALY for erlotinib was -£7106, with an NMB of £1181, which implies that erlotinib confers greater effectiveness at a lower cost than docetaxel. This advantage was maintained when equivalent PFS with The strengths of the present evaluation include the way in which the model structure mirrors the natural progression of advanced NSCLC as reflected in the phase III studies. The model is also based on reasonably complete follow-up data from two phase III studies; 7,17 therefore, no extrapolation of survival data, with its associated uncertainty, was necessary. A limitation of the evaluation lies in the fact that this was an indirect comparison using data from two separate trials but this approach was used because of the absence of a direct comparison between the two drugs assessed. Due to the nature of the decision making problems faced by the health service and prescribers, some form of evaluation and judgement on relative efficacy must still be made. The issues of selection bias generated via such an indirect comparison are addressed, at least in part, by comparing the baseline characteristics from the two phase III studies; the differences in baseline performance status between the two populations are likely to have favoured docetaxel. Furthermore, the mean survival for docetaxel, as reported by Holmes et al, 22 was an unrestricted mean since all patients had died by 19.3 months in the TAX317 study. In contrast, after 24 months, approximately 13% of erlotinib-treated patients were still alive in the BR.21 study. The mean overall survival assumed for erlotinib is, therefore, an underestimate.
In a recently published paper, Hawkins et al. 25 explored the impact of widening the network of trial evidence used to inform a formal network meta-analysis of docetaxel and erlotinib with respect to the overall survival endpoint. They demonstrated that • Revised accepted 20 November 2009 Copyright © 2010 Field House Publishing LLP "widening the scope of an indirect comparison to incorporate trials including comparators other than those of immediate interest can improve precision and alter the final results; in this case swapping the ranking of the estimated mean treatment effects for docetaxel and erlotinib", and suggested that "erlotinib may be associated with better outcomes".
With respect to further research, an ongoing randomized phase III study (TITAN) is assessing the use of erlotinib versus chemotherapy (docetaxel or pemetrexed) in the second-line treatment of advanced NSCLC; data from this trial could potentially be used to reduce uncertainty in the relative survival estimates of both docetaxel and erlotinib. Further refinements would be possible with the availability of prospectively collected resource utilization data and evidence relating to the exact duration of QoL decrements following treatment-related adverse events.
The ideal second-line treatment for advanced NSCLC would relieve disease symptoms, improve QoL, extend survival, have a good tolerability profile and be convenient to administer. Currently available chemotherapy options in the UK, however, provide limited symptomatic and QoL benefits, have considerable haematological toxicity and require comedication to reduce toxicity. Growing demand and pressure on NHS facilities for intravenous chemotherapy 36 also suggests that added healthcare capacity and productivity benefits would result from the adoption of oral medications.
The cost-effectiveness findings of the present analysis are supported by health economic analyses of erlotinib from the perspective of healthcare providers in other countries. Similar findings have been demonstrated in The Netherlands, 37 Poland 38 and Spain, 39 and cost-savings versus docetaxel have been shown in Germany. 40 A cost analysis from a US healthcare payer's perspective has indicated that the direct cost of erlotinib is offset by reductions in the costs of administration and management of adverse events with standard chemotherapy. 41 In summary, erlotinib appears to generate similar overall survival, an increase in QALYs and a small reduction in total NHS costs compared with docetaxel, due to lower adverse event and drug administration costs. Consequently, from a health economics perspective, for the treatment of relapsed stage III -IV NSCLC patients in the UK, erlotinib has advantages over docetaxel.
